Psoriasis and comorbid diseases

Epidemiology

Junko Takeshita, MD, PhD, MSCE, Sungat Grewal, BS, Sinéad M. Langan, MB, BCh, BAOC, MRCP, MSc, PhD, Nehal N. Mehta, MD, MSCE, Alexis Ogdie, MD, MSCE, Abisy J. Van Voorhees, MD, and Joel M. Gelfand, MD, MSCE.

Philadelphia, Pennsylvania; London, United Kingdom; Bethesda, Maryland; and Norfolk, Virginia

See related articles on pages 393 and 531

Learning objectives

After completing this learning activity, participants should be able to list at least five comorbidities that are associated with psoriasis, and discuss the supporting evidence and identify psoriasis patients who have the greatest risk of developing cardiovascular disease.

Disclosures

The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

The authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Psoriasis is a common chronic inflammatory disease of the skin that is increasingly being recognized as a systemic inflammatory disorder. Psoriatic arthritis is a well-known comorbidity of psoriasis. A rapidly expanding body of literature in various populations and settings supports additional associations between psoriasis and cardiometabolic diseases, gastrointestinal diseases, kidney disease, malignancy, infection, and mood disorders. The pathogenesis of comorbid disease in patients with psoriasis remains unknown; however, shared inflammatory pathways, cellular mediators, genetic susceptibility, and common risk factors are hypothesized to be contributing elements. As additional psoriasis comorbidities continue to emerge, education of health care providers is essential to ensuring comprehensive medical care for patients with psoriasis. (J Am Acad Dermatol 2017;76:377-90.)

Key words: cardiovascular disease; chronic kidney disease; comorbidities; Crohn's disease; depression; metabolic syndrome; nonalcoholic fatty liver disease; psoriasis; psoriatic arthritis; lymphoma; infection.

From the Departments of Dermatology, Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics, and Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia; London School of Hygiene and Tropical Medicine and St. John's Institute of Dermatology, London; National Heart, Lung and Blood Institute, Bethesda; and the Department of Dermatology, Eastern Virginia Medical School, Norfolk.

Supported in part by National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K24AR064310 (Dr. Gelfand), T32AR00746532 (Ms. Grewal), K23AR063764 (Dr. Ogdie), and K23AR068433 (Dr. Takeshita), a Dermatology Foundation Career Development Award (Dr. Takeshita), the Intramural Research Program at the National Institutes of Health grant ZIAHL006193-02 (Mehta), and a National Institute for Health Research Clinician Scientist Fellowship (grant NIHR/CS/010/014 to Dr. Langan). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the UK Department of Health.

Dr. Takeshita has received a research grant (to the Trustees of the University of Pennsylvania) from Pfizer Inc and payment for continuing medical education work related to psoriasis. Dr. Mehta is a full-time employee of the US Government. Dr. Ogdie receives research grants from AbbVie (to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis [GRAPPA]), Celgene (to GRAPPA), and Pfizer Inc (to the Trustees of the University of Pennsylvania and GRAPPA), and has served as a consultant for Novartis, receiving honoraria. Dr. Van Voorhees has served as a consultant for AbbVie, Amgen, AstraZeneca, Celgene, Corrona, Dermira, Janssen, Leo, Novartis, and Pfizer, receiving honoraria; received a research grant from AbbVie; and has other relationships with Merck. Dr. Gelfand has served as a consultant for AbbVie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Endo, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Amgen, Eli Lilly, Janssen, Novartis Corp, Regeneron, and Pfizer Inc; and received payment for continuing medical education work related to psoriasis. Dr. Gelfand is a co-patient holder of resiquimod for treatment of cutaneous T-cell lymphoma. No other potential conflicts of interest were declared by the authors.

Accepted for publication July 1, 2016.

Correspondence to: Junko Takeshita, MD, PhD, MSCE, Department of Dermatology, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, 7th Floor, South Tower, Office 728, Philadelphia, PA 19104. E-mail: Junko.Takeshita@uphs.upenn.edu. 0190-9622/536.00

© 2016 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

http://dx.doi.org/10.1016/j.jaad.2016.07.064

Date of release: March 2017
Expiration date: March 2020
INTRODUCTION

Psoriasis is a common chronic inflammatory disease that affects >7.5 million people in the United States and approximately 125 million people worldwide.\(^1-3\) It has significant impacts on both physical and emotional health-related quality of life comparable to other major illnesses.\(^4\) In the last decade, tremendous progress has been made in furthering our understanding of the genetics, pathophysiology, and treatment of psoriasis. Epidemiologic and basic scientific evidence contributing to our knowledge of the natural history and biology of psoriasis, respectively, have led to the recognition of psoriasis as a disorder with important health implications that extend beyond the skin.

The first observation of comorbid disease among patients with psoriasis was made in 1897 when Strauss\(^5\) reported an association between psoriasis and diabetes. In 1961, Reed et al\(^6\) described a high prevalence of heart disease including coronary thrombosis and myocardial infarction (MI) in postmortem examinations of psoriasis patients with psoriatic arthritis (PsA). Subsequently, in 1978, McDonald et al\(^7\) observed an increased prevalence of venous and arterial vascular disease in hospitalized patients with psoriasis. Now many years later, a quickly evolving body of literature using modern epidemiologic techniques has shown that psoriasis, particularly severe disease, is associated with increased mortality\(^8\) and comorbid disease burden\(^9,10\) that are hypothesized to be the result of chronic inflammation associated with the skin disease.

We review the epidemiologic data supporting associations between psoriasis and cardiometabolic diseases, gastrointestinal diseases, kidney disease, malignancy, infection, mood disorders, PsA, and other emerging comorbid diseases. Recognition of the comorbid disease burden associated with psoriasis is essential for comprehensive medical care for patients with this chronic skin disorder.

CARDIOMETABOLIC DISEASE

Key points

- Cardiometabolic disease is prevalent among patients with psoriasis, especially those with more severe skin disease
- Psoriasis may be an independent risk factor for diabetes and major adverse cardiovascular events; the risk of a major adverse cardiovascular event is greatest among those with severe psoriasis
- Chronic systemic, specifically vascular, inflammation may be increased in patients with psoriasis and may contribute to atherogenesis

Major adverse cardiovascular events

Cardiovascular (CV) risk factors are prevalent among patients with psoriasis, and therefore an increased risk of CV disease (CVD) may be expected. However, in 2006, a large, population-based cohort study in the United Kingdom found that psoriasis was associated with an increased risk of MI, independent of traditional risk factors, such as body mass index (BMI), smoking, hypertension, diabetes, and dyslipidemia.\(^11\) Moreover, a dose-response effect was shown, with stronger, more clinically significant risk in patients with more severe disease as defined by receipt of phototherapy or systemic therapies indicated for severe psoriasis. Subsequently, numerous epidemiologic studies have similarly suggested psoriasis to be an independent risk factor for MI, stroke, and death caused by CVD, collectively termed major adverse cardiovascular events (MACE). While a few studies have reported non-statistically significant associations between psoriasis and MACE,\(^12-15\) as discussed in detail elsewhere,\(^16-18\) results from these studies remain consistent with the larger body of work that have found statistically significant associations. To date, many of the studies have been summarized in ≥1 of 8 meta-analyses of psoriasis and CVD (Table I).\(^19-26\) Two meta-analyses\(^19,25\) specifically examined the risks of MI, stroke, and CV mortality according to psoriasis severity and reported the greatest risks to be among those with severe disease. Risk of MI among patients

Abbreviations used:

- BMI: body mass index
- BSA: body surface area
- CAD: coronary artery disease
- CD: Crohn’s disease
- CEC: cholesterol efflux capacity
- CHD: coronary heart disease
- CKD: chronic kidney disease
- CTCL: cutaneous T-cell lymphoma
- CV: cardiovascular
- CVD: cardiovascular disease
- ESRD: end-stage renal disease
- FDG: fluorodeoxyglucose
- FRS: Framingham Risk Score
- HDL: high-density lipoprotein
- IBD: inflammatory bowel disease
- IHD: ischemic heart disease
- MACE: major adverse cardiovascular events
- MI: myocardial infarction
- NAFLD: nonalcoholic fatty liver disease
- NASH: nonalcoholic steatohepatitis
- NMSC: nonmelanoma skin cancer
- OR: odds ratio
- PET/CT: positron emission tomography/computed tomography
- PsA: psoriatic arthritis
- RA: rheumatoid arthritis
- RR: relative risk or risk ratio
- UC: ulcerative colitis
with mild psoriasis was found to be significantly increased in both meta-analyses,\textsuperscript{19,25} albeit to a lesser extent, suggesting that CV risk is not limited to those with severe disease. Longer duration of psoriasis has also been associated with increased risk of CVD.\textsuperscript{27-28} Collectively, these data provide evidence for psoriasis as an independent risk factor for CVD.

Additional analyses have identified the clinical importance of and provided practical measures for the increased risk of MACE associated with psoriasis.\textsuperscript{29,30} In a cohort study of severe psoriasis patients in the United Kingdom, Mehta et al\textsuperscript{29} found the attributable risk of severe psoriasis on MACE over a 10-year period to be 6.2%. Importantly, in a study to determine the impact of psoriasis on the Framingham Risk Score (FRS), adding psoriasis to the FRS resulted in reclassification of a majority of patients to a higher CV risk category whereby 75% of patients at low risk were reclassified as intermediate risk and 53% of patients at intermediate risk were reclassified as high risk.\textsuperscript{31} Putting the psoriasis-associated CV risk into context with other chronic inflammatory diseases, Ahlehoff et al\textsuperscript{30} found the increased risk of MACE associated with severe psoriasis to be nearly identical to that conferred by diabetes alone. Similarly, a single observational study of patients with either rheumatoid arthritis (RA) or psoriasis suggests that patients treated with similar systemic treatments (eg, methotrexate) each have similarly elevated risks of MACE, independent of traditional risk factors.\textsuperscript{32}

Shared pathophysiologic pathways between psoriasis and CVD, including chronic type 1 helper (T\textsubscript{H}1) T cell- and T\textsubscript{H}17-mediated inflammation,\textsuperscript{33-38} monocyte and neutrophil modulation,\textsuperscript{39-41} increased oxidative stress,\textsuperscript{35} endothelial cell dysfunction,\textsuperscript{42} increased uric acid,\textsuperscript{13,44} angiogenesis,\textsuperscript{45} and increased circulating microparticles\textsuperscript{45-48} may explain the increased CVD risk associated with psoriasis. In addition, persistent pathophysiologic processes that drive psoriasis (eg, epidermal hyperproliferation, inflammation,\textsuperscript{49,50} and angiogenesis) may also exert pleiotropic adverse effects on the CV system that contribute to atherogenesis. Mouse models of psoriasis have shown that chronic skin-specific inflammation has systemic effects, including arterial hypertension,\textsuperscript{51} endothelial dysfunction,\textsuperscript{51} and vascular inflammation and thrombosis.\textsuperscript{38} Studies in psoriasis patients yield similarly consistent findings using \textsuperscript{18}F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), a sensitive tool for measuring vascular inflammation and visualizing macrophage activity in vivo. Aortic inflammation measured by PET/CT is a predictor of future CV events and has been shown to rapidly decrease when patients are exposed to interventions known to lower CV risk (ie, statin therapy), making it an attractive surrogate endpoint to study.\textsuperscript{52} Aortic inflammation has been observed to be increased in psoriasis patients in a manner that is independent of CV risk factors and correlates with severity of skin disease,\textsuperscript{53} lending further support to the idea that inflammatory pathways in psoriasis exert systemic effects. Lastly, common genetics between psoriasis, diabetes, and CVD, such as CDKAL1, ApoE4, and others, have been suggested,\textsuperscript{54-64} and genes relevant to metabolic disease and CVD have been found to be dysregulated in lesional skin and in the serum of psoriasis patients.\textsuperscript{64-66} On the other hand, other work suggests that shared genetic pathways are unlikely to explain the association between psoriasis and CVD.\textsuperscript{67}

**Obesity**

Obesity is an independent risk factor for psoriasis. In studies of incident psoriasis,\textsuperscript{68-70} the risk of psoriasis was found to increase with higher BMI.\textsuperscript{59} A meta-analysis of 16 observational studies found a pooled odds ratio (OR) for the association between psoriasis and obesity to be 1.66 (95% confidence interval [CI], 1.46-1.89; Table II).\textsuperscript{71} Among studies that accounted for psoriasis severity, generally defined by treatment patterns, the pooled ORs for the association between obesity and mild and severe psoriasis were 1.46 (95% CI, 1.17-1.82) and 2.23 (95% CI, 1.63-3.05), respectively. As further support for a relationship between psoriasis severity and obesity, Langan et al\textsuperscript{72} performed a cross-sectional study of patients with psoriasis in the United Kingdom for whom information on body surface area (BSA) involvement by psoriasis was available and found a positive dose-dependent relationship between objective measures of psoriasis severity and obesity.\textsuperscript{72}

**Hypertension**

Hypertension is more prevalent among patients with versus without psoriasis. A meta-analysis of 24 observational studies found a pooled OR for the association between psoriasis and hypertension to be 1.58 (95% CI, 1.42-1.76).\textsuperscript{73} The odds of hypertension among patients with psoriasis increased with greater disease severity with ORs of 1.30 (95% CI, 1.15-1.47) for mild and 1.49 (95% CI, 1.20-1.86) for severe psoriasis as defined by treatment patterns.\textsuperscript{72} Two cohort studies also observed psoriasis to be associated with an increased risk of incident hypertension.\textsuperscript{74,75}

Importantly, studies of patients with hypertension suggest more severe hypertension and poorly controlled blood pressure among patients with
<table>
<thead>
<tr>
<th>Study</th>
<th>Study dates</th>
<th>No. of studies</th>
<th>Total no. of patients</th>
<th>Outcome</th>
<th>Composite measure of association (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Psoriasis</td>
<td>No psoriasis</td>
</tr>
<tr>
<td>Armstrong et al\textsuperscript{19} \textsuperscript{19}</td>
<td>January 1, 1980 to January 1, 2012</td>
<td>9</td>
<td>Mild: 201,239</td>
<td>Severe: 17,415</td>
<td>9,914,799</td>
</tr>
<tr>
<td>Gaeta et al\textsuperscript{20} \textsuperscript{20}</td>
<td>NR</td>
<td>13</td>
<td>1,862,297</td>
<td>43,407,300</td>
<td>CV risk: MI, vascular disease, and mortality</td>
</tr>
<tr>
<td>Gu et al\textsuperscript{21} \textsuperscript{21}</td>
<td>1966 to October 2012</td>
<td>15</td>
<td>Total (psoriasis + no psoriasis): 6,230,774</td>
<td>MI, stroke, CVD, and CV mortality</td>
<td></td>
</tr>
<tr>
<td>Horreau et al\textsuperscript{22} \textsuperscript{22}</td>
<td>1980 to December 211</td>
<td>33</td>
<td>324,650</td>
<td>5,309,087</td>
<td>MI, CAD, and stroke</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Time Period</td>
<td>Study Size</td>
<td>Follow-up</td>
<td>CVD, IHD, Cerebrovascular disease, and CV mortality</td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>--------------------</td>
<td>------------</td>
<td>-----------</td>
<td>-----------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Miller et al (2013)*</td>
<td>Before October 25, 2012</td>
<td>75</td>
<td>503,686</td>
<td>29,686,694</td>
<td></td>
</tr>
<tr>
<td>Pietrzak et al (2013)</td>
<td>1960 to 2011</td>
<td>14</td>
<td>367,358</td>
<td>9,199,656</td>
<td></td>
</tr>
</tbody>
</table>

**Results:**
- CVD: OR 1.4 (1.2-1.7)
- IHD: OR 1.5 (1.2-1.9)
- Cerebrovascular disease: 1.1 (0.9-1.3)
- CV mortality: 0.9 (0.4-2.2)
- CV events: MI, IHD, cerebral ischemic stroke, and sudden cardiac death: OR 1.28 (1.18-1.38)
- All psoriasis: HR/IRR 1.40 (1.03-1.89)
- Mild psoriasis: HR/IRR 1.34 (1.07-1.68)
- Severe psoriasis: HR/IRR 3.04 (0.65-14.35)
- MI: All psoriasis: HR/IRR 1.13 (1.01-1.26)
- Mild psoriasis: HR/IRR 1.15 (0.98-1.35)
- Severe psoriasis: HR/IRR 1.59 (1.34-1.89)
- Stroke: All psoriasis: SMR 1.03 (0.86-1.25)
- Mild psoriasis: SMR 1.37 (1.17-1.60)
- Severe psoriasis: SMR 1.57 (1.26-1.96)

**Abbreviations:**
- **CAD:** Coronary artery disease
- **CHD:** Coronary heart disease
- **CV:** Cardiovascular
- **CVD:** Cardiovascular disease
- **HR:** Hazard ratio
- **IHD:** Ischemic heart disease
- **IRR:** Incidence rate ratio
- **MACE:** Major adverse cardiovascular event
- **MI:** Myocardial infarction
- **OR:** Odds ratio
- **RR:** Relative risk or risk ratio

*Systematic review and meta-analysis of the association between psoriasis and CVD and cardiovascular risk factors. Total numbers of studies and patients included are as reported in the full systematic review and meta-analysis, a subset of which is specifically relevant to psoriasis and CVD.
<table>
<thead>
<tr>
<th>Study</th>
<th>Study dates</th>
<th>Total no. of patients</th>
<th>No. of studies included</th>
<th>CV risk factor</th>
<th>Composite measure of association (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Psoriasis</td>
<td>No psoriasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Armstrong et al</td>
<td>January 1, 1980 to January 1</td>
<td>201,831</td>
<td>2,119,329</td>
<td>Total: 16</td>
<td>Obesity Overall: OR 1.66 (1.46-1.89);</td>
</tr>
<tr>
<td></td>
<td>2012</td>
<td></td>
<td></td>
<td>Severity assessment: 5</td>
<td>mild: OR 1.46 (1.17-1.82); severe: OR 2.23 (1.63-3.05); incidence: HR 1.18 (1.14-1.23)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Incidence: 1</td>
<td></td>
</tr>
<tr>
<td>Armstrong et al</td>
<td>January 1, 1980 to January 1</td>
<td>309,469</td>
<td>2,384,229</td>
<td>Total: 24</td>
<td>Hypertension Overall: OR 1.58 (1.42-1.76);</td>
</tr>
<tr>
<td></td>
<td>2012</td>
<td></td>
<td></td>
<td>Severity assessment: 5</td>
<td>mild: OR 1.30 (1.15-1.47); severe: OR 1.49 (1.20-1.86); incidence: HR 1.09 (1.05-1.14); incidence: RR 1.17 (1.06-1.30)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Incidence: 2</td>
<td></td>
</tr>
<tr>
<td>Armstrong et al</td>
<td>January 1, 1980 to January 1</td>
<td>404,494</td>
<td>4,640,847</td>
<td>Total: 27</td>
<td>Diabetes Overall: OR 1.59 (1.38-1.83);</td>
</tr>
<tr>
<td></td>
<td>2012</td>
<td></td>
<td></td>
<td>Severity assessment: 5</td>
<td>mild: OR 1.53 (1.16-2.04); severe: OR 1.97 (1.48-2.62); incidence: RR 1.27 (1.16-1.40)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Incidence: 5</td>
<td></td>
</tr>
<tr>
<td>Ma et al</td>
<td>January 1, 1980 to January 1</td>
<td>265,685</td>
<td>2,167,198</td>
<td>Total: 25</td>
<td>Dyslipidemia Overall: OR 1.04-5.55;</td>
</tr>
<tr>
<td></td>
<td>2012</td>
<td></td>
<td></td>
<td>Severity assessment: 5</td>
<td>mild: OR 1.10-3.38; severe: OR 1.26-5.55</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Incidence: 1</td>
<td></td>
</tr>
<tr>
<td>Armstrong et al</td>
<td>January 1, 1980 to January 1</td>
<td>41,853</td>
<td>1,357,324</td>
<td>Total: 12</td>
<td>Metabolic syndrome Overall: OR 2.26 (1.70-3.01);</td>
</tr>
<tr>
<td></td>
<td>2013</td>
<td></td>
<td></td>
<td>Severity assessment: 3</td>
<td>mild: OR 1.22 (1.11-1.35); moderate OR: 1.56 (1.38-1.76); severe OR: 1.98 (1.62-2.43)</td>
</tr>
</tbody>
</table>

CI, Confidence interval; CV, cardiovascular; HR, hazard ratio; OR, odds ratio; RR, relative risk.

*Reported from single study by Langan et al.72

†Systematic review only.
psoriasis compared with those without psoriasis. In addition, the likelihood of poorly controlled hypertension appears to increase with more severe skin disease, independent of BMI and other risk factors.

**Diabetes**

Psoriasis is associated with an increased risk of diabetes, independent of traditional risk factors. A meta-analysis of 5 cohort studies assessing the risk of incident diabetes among patients with psoriasis found a pooled relative risk (RR) for diabetes of 1.27 (95% CI, 1.16-1.40). The risk of diabetes and likelihood of insulin resistance and diabetic complications are suggested to increase with greater psoriasis severity as defined by treatment patterns or BSA affected, respectively, independent of traditional risk factors, such as BMI. Moreover, diabetic patients with psoriasis appear to be more likely to require pharmacologic management and suffer from micro- and macrovascular diabetes complications than diabetic patients without psoriasis.

**Dyslipidemia**

Dyslipidemia may be more prevalent among patients with than without psoriasis. In a systematic review, 20 of 25 included studies found significant associations between psoriasis and dyslipidemia, with ORs ranging from 1.04 to 5.55. Among 3 of the studies included in the systematic review, the ORs for dyslipidemia ranged from 1.10 to 3.38 for patients with mild psoriasis and from 1.36 to 5.55 for patients with severe psoriasis. The directionality of the association between the 2 conditions remains unclear; some studies suggest dyslipidemia may be a risk factor for developing psoriasis.

Advanced lipid testing techniques have shown a more atherogenic lipid profile and decreased high density lipoprotein (HDL) cholesterol efflux capacity (CEC) among patients with versus without psoriasis, beyond CV risk factors. Increasing psoriasis severity is negatively correlated with HDL CEC in both adults and children with psoriasis. HDL CEC is also directly related to coronary artery disease burden in patients with psoriasis and is suggested to be an important proxy for vascular disease.

**Metabolic syndrome**

Metabolic syndrome is generally defined by the presence of a combination of central obesity, hypertension, insulin resistance, and dyslipidemia. Studies have found metabolic syndrome and its individual components to be more prevalent among patients with than without psoriasis in both adult and pediatric populations. A meta-analysis of 12 observational studies found a pooled OR of 2.26 (95% CI, 1.70-3.01) for the association between psoriasis and metabolic syndrome, but the analysis was limited by the presence of publication bias due to an absence of smaller studies in the published literature. Importantly, in Langan et al’s cross-sectional study in the United Kingdom, the prevalence of metabolic syndrome correlated directly with BSA affected by psoriasis.

**GASTROINTESTINAL DISEASE**

**Key points**

- Psoriasis may be associated with an increased incidence and prevalence of inflammatory bowel disease, particularly Crohn’s disease
- Few studies suggest that psoriasis is associated with an increased prevalence of hepatic diseases, particularly nonalcoholic fatty liver disease

**Inflammatory bowel disease**

Common genetic and inflammatory pathways have been implicated in psoriasis and IBD, which includes Crohn’s disease (CD) and ulcerative colitis (UC). The epidemiology of this relationship remains poorly defined. Several studies have observed increased prevalence and incidence of IBD among patients with psoriasis and vice versa, with varying degrees of association, and a Taiwanese study suggested an absence of association. Cohen et al observed that psoriasis may be more strongly associated with CD than UC (ORs 2.49 [95% CI, 1.71-3.62] and 1.64 [95% CI, 1.15-2.23], respectively). Similarly, a cohort study of US women found an increased risk of CD among patients with psoriasis (RR, 3.86 [95% CI, 2.23-6.67]), while the risk of UC was attenuated and not statistically significant (RR, 1.17 [95% CI, 0.41-3.36]).

**Hepatic disease**

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease in Western industrialized countries and encompasses a spectrum of liver disorders from mild hepatic steatosis to nonalcoholic steatohepatitis (NASH). Associations between psoriasis and NAFLD have been reported in the literature. In a meta-analysis of 7 observational studies that were considered low to moderate quality and, for the most part, did not adjust for potential confounding factors, such as metabolic syndrome, NAFLD was found to be more prevalent among patients with versus without psoriasis (pooled OR, 2.15 [95% CI, 1.57-2.94]). Beyond NAFLD, a cross-sectional study in the United Kingdom found that psoriasis was associated with a higher prevalence of...
“mild” liver disease, including chronic hepatitis, alcoholic liver disease, and NAFLD (OR, 1.41 [95% CI, 1.12-1.76]). A positive dose-response relationship between psoriasis severity based on BSA involvement and “mild” liver disease was also seen.

CHRONIC KIDNEY DISEASE
Key points

- Moderate to severe psoriasis may be an independent risk factor for chronic kidney disease and end-stage renal disease
- The odds of chronic kidney disease increase in a dose-dependent manner with greater psoriasis severity

The term “psoriatic nephropathy” was first introduced based on case reports of glomerulonephritis in patients with psoriasis. Until recently, most studies assessing the association between psoriasis and kidney disease have been small and cross-sectional, with varying results. In a UK cohort study of cause-specific mortality among patients with psoriasis, severe psoriasis was associated with a 4-fold increased risk of death from nephritic or nonhypertensive kidney disease. A Swedish cohort study also found mild psoriasis to be associated with more than a 2-fold increased risk of death from kidney disease. In 2013, another UK cohort study found that severe psoriasis may, in fact, be a risk factor for chronic kidney disease (CKD) and end-stage renal disease (ESRD), independent of traditional risk factors, such as age, sex, BMI, CVD, diabetes, hypertension, hyperlipidemia, and nephrotoxic medications (hazard ratio [HR] for CKD 1.93 [95% CI, 1.79-2.08]; HR for ESRD, 4.15 [95% CI, 1.70-10.11]). A nested cross-sectional analysis of patients with psoriasis for whom information on BSA involvement was available found the prevalence of CKD to increase in a dose-dependent manner with more severe psoriasis. A cohort study in Taiwan similarly found severe psoriasis to be associated with nearly 2- and 3-fold increased risks of CKD and ESRD, respectively.

MALIGNANCY
Key points

- Psoriasis, particularly severe disease, may be associated with an increased risk of cancer
- Lymphoma has been most consistently associated with psoriasis, and risk of cutaneous T-cell lymphoma is suggested to be the highest

Patients receiving treatments for severe psoriasis have a 41% increased risk of dying from malignancy than patients without psoriasis. Risk of malignancy attributable to psoriasis itself remains uncertain. A meta-analysis of 11 observational studies evaluating the risk of malignancy among patients with psoriasis suggested that overall risk of cancer, excluding nonmelanoma skin cancers (NMSCs), is increased (standardized incidence ratio, 1.16 [95% CI, 1.07-1.25]). Greater risks of upper aerodigestive tract, respiratory tract, liver, pancreas, urinary tract cancers, and lymphoma were also suggested. The level of heterogeneity among the included studies was high, making interpretation challenging. In addition, many studies did not account for important confounding factors, such as smoking and drinking, or assess psoriasis treatment effects on the risk of subsequent malignancy, calling into question the validity of attributing the increased risk of cancer to psoriasis alone. A subsequent cohort study of cancer risk among patients with psoriasis in the United Kingdom that included information on BMI, smoking, and drinking also found increased risks of lung cancer, NMSC, and lymphoma, supporting some of Pouplard et al’s findings. The greatest risks of cancer were among those receiving treatments for severe psoriasis. The association between psoriasis and lung cancer was lost, however, after stratification by smoking status. Additional studies assessing lymphoma risk in patients with psoriasis also found persistently increased risks of lymphoma (1.3- to 2-fold increased risk) even among those without a history of immunosuppressive therapy, although absolute risks remained low. Of the specific lymphoma types, the association between psoriasis and cutaneous T-cell lymphoma (CTCL) was suggested to be the strongest. It remains unclear what role psoriasis therapies or misdiagnosis of CTCL as psoriasis may play in explaining this observation.

INFECTION
Key points

- Streptococcal pharyngitis is a trigger of guttate psoriasis, and exacerbation of psoriasis in the setting of HIV infection is known
- Psoriasis may be associated with an increased risk of serious infection (ie, infection requiring hospitalization), especially respiratory infections

Infection is the second-leading cause of excess death among patients who are receiving therapies for severe psoriasis, and patients with severe psoriasis have a 65% increased risk of dying from infection than patients without psoriasis. With the advent of targeted biologic therapies, much attention has been
paid to measuring the risk of infection associated with these therapies for psoriasis. However, infection risk attributable to psoriasis itself remains poorly understood. The most well-recognized association between psoriasis and infection is that of guttate psoriasis and streptococcal pharyngitis, which is thought to be caused by molecular mimicry between streptococcal M peptides and human keratins. Exacerbation of psoriasis in the setting of HIV infection has also been documented. The risk of serious infection among patients with psoriasis has only more recently been evaluated. A Dutch cohort study found psoriasis to be independently associated with an increased risk of serious infection (HR, 1.54 [95% CI, 1.44-1.65]) whereby the greatest risk was among patients with severe psoriasis as defined by treatment patterns (HR, 1.81 [95% CI, 1.57-2.08]). Respiratory tract, abdominal, and skin infections were the most common infections among patients with psoriasis. Similarly, a cohort study in Taiwan reported an increased risk of hospitalized pneumonia among patients with psoriasis, independent of other potential risk factors for pneumonia (HR, 1.40 [95% CI, 1.12-1.73]). Severe psoriasis was associated with the greatest risk of hospitalized pneumonia (HR, 1.68 [95% CI, 1.12-2.52]). While neither study had access to information on potential confounders, such as obesity, smoking, and drinking, subsequent cohort studies in the United Kingdom that included this information confirmed that psoriasis is associated with an increased risk of serious infection including hospitalized pneumonia, and further suggested that this risk may increase with greater BSA involvement by psoriasis.

MOOD DISORDERS

Key points

- Mood disorders are common among patients with psoriasis
- Psoriasis is associated with an increased risk of depression, anxiety, and suicidal ideation

Psoriasis has a major impact on patients’ physical and emotional health-related quality of life comparable to other major illnesses, and this may predispose patients to the development of mood disorders, such as depression, anxiety, and suicidality. Mood disorders, particularly depression, have been suggested to be more prevalent in patients with psoriasis than in the general population (up to 62% prevalence). In a meta-analysis of 98 mostly cross-sectional studies examining the association between psoriasis and depression, patients with psoriasis had more depressive symptoms (pooled standardized mean difference, 1.16 [95% CI, 0.67-1.66]) and were nearly 1.6-fold more likely to experience depression (pooled OR, 1.57 [95% CI, 1.40-1.76]) than patients without psoriasis.

The risk of depression in psoriasis has been evaluated in 2 cohort studies. In a UK study, psoriasis was found to be associated with increased risks of depression (HR, 1.39 [95% CI, 1.37-1.41]), anxiety (HR, 1.31 [95% CI, 1.29-1.34]), and suicidality (HR, 1.44 [95% CI, 1.32-1.57]). The risk of depression was greatest among patients who were receiving therapies for severe psoriasis (HR, 1.72 [95% CI, 1.57-1.88]). Similarly, a study of women in the Nurses’ Health Study found psoriasis to be associated with a nearly 30% increased risk of depression (RR, 1.29 [95% CI, 1.10-1.52]), independent of age, BMI, lifestyle factors, and comorbid conditions.

PSORIATIC ARTHRITIS

Key points

- Psoriatic arthritis is an inflammatory arthritis that is present in 6% to 42% of patients with psoriasis
- Psoriatic arthritis is more prevalent among patients with more extensive skin disease
- Approximately 15% of patients with psoriasis have undiagnosed psoriatic arthritis

Psoriatic arthritis (PsA) is the most well-recognized comorbidity of psoriasis and is a heterogeneous inflammatory arthritis characterized by joint or enthesal inflammation and extra-articular manifestations. The prevalence of inflammatory arthritis in patients with psoriasis ranges from 6% to 42% depending on the definitions used and populations studied. The prevalence of PsA increases with greater psoriasis severity and duration; however, the severity of skin disease is only weakly associated with severity of joint disease. PsA has been associated with the distribution of psoriasis involvement (ie, scalp, intergluteal, and perianal) and the presence of nail dystrophy, which is suggested to indicate early enthesal inflammation.

The diagnosis of PsA can be especially challenging. The differential diagnosis includes osteoarthritis, RA, crystal arthropathy (eg, gout or calcium pyrophosphate disease), and fibromyalgia. Undiagnosed PsA among patients with psoriasis seen in the dermatology setting is prevalent and estimated at 15.5%. PsA generally occurs after the onset of psoriasis and can be progressive and result in permanent joint damage. Therefore, early detection is essential because early treatment improves outcomes. The varied clinical features of and classification criteria for PsA...
and its associations with cardiometabolic and other comorbid diseases are reviewed elsewhere.\textsuperscript{123,150}

**EMERGING COMORBIDITIES**

**Key point**

- Other emerging comorbidities of psoriasis include chronic obstructive pulmonary disease, peptic ulcer disease, sexual dysfunction, and obstructive sleep apnea

Additional epidemiologic studies have suggested associations between psoriasis and other emerging comorbid conditions, including chronic obstructive pulmonary disease,\textsuperscript{9,151,152} peptic ulcer disease,\textsuperscript{9,153} sexual dysfunction,\textsuperscript{154} and obstructive sleep apnea,\textsuperscript{155-157} among others. Further characterization of known comorbidities and identification of new comorbidity associations with psoriasis are anticipated as research efforts continue.

In summary, it is essential for both clinicians and patients to recognize the potentially heightened risk of CVD and other comorbidities associated with psoriasis that may increase with greater disease severity and duration. Particularly as psoriasis remains largely undertreated,\textsuperscript{158,159} the disease remains active for decades in most patients, potentially placing them at increased risk for associated comorbidities and mortality. Patient and provider education and increased awareness of psoriasis comorbidities are critical to improving the care and quality of life for those living with psoriasis.

The authors thank Jina Chung, MD, for her early contributions to the preparation of the manuscript.

**REFERENCES**


93. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007;447:661-678.


